Arkin Bio Ventures

Arkin Bio Ventures is a Tel Aviv-based life sciences venture capital firm founded in 2016 as part of Arkin Capital, a diversified global investment manager with over $2 billion in assets under management across twelve funds. Arkin Bio operates as a joint venture between Phoenix Group (49%) and Arkin Holdings (51%), and has raised three funds: Fund I in 2016, Fund II at $140 million in 2020, and Fund III at $100 million closed in January 2026 — bringing total life sciences AUM above $600 million. Managing Partner Dr. Pini Orbach and Partner Alon Lazarus lead a team of ten, including four partners. The firm leads rounds and invests $3 million to $20 million per company at early and mid-stage in biotech companies developing therapies in immunotherapy, cancer, metabolism, microbiome, autoimmune diseases, and drug delivery. With 27-plus investments and more than 20 successful exits through IPOs and acquisitions, Arkin Bio has backed UroGen Pharma, Keros Therapeutics, Bluejay Therapeutics, cCAM Biotherapeutics, Hi-Bio, and ImmPACT Bio, among others. Arkin Bio's partnership with Phoenix Group provides co-investment capacity that extends individual deal capability and supports portfolio companies through multiple rounds. The team works closely with founders on biological strategy, translational planning, and clinical positioning — going well beyond check-writing to serve as active scientific and commercial advisors during the most capital-intensive stages of drug development.